BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29144798)

  • 1. PANCREAS METASTASES FROM PAPILLARY THYROID CARCINOMA: A REVIEW OF THE LITERATURE.
    Davidson M; Olsen RJ; Ewton AA; Robbins RJ
    Endocr Pract; 2017 Dec; 23(12):1425-1429. PubMed ID: 29144798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
    Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
    Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: A New Entity: Multiple Differentiated Variant of Papillary Thyroid Carcinoma With Advanced Clinical Behavior.
    Yang J; Gong R; Ma Y; Gao J; Li Z; Zhu J; Gong Y
    Front Endocrinol (Lausanne); 2021; 12():654638. PubMed ID: 33897621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic metastasis from papillary thyroid carcinoma: Case report and literature review.
    Stein R; Harmon TS; Harmon CE; Kuo E; Ozdemir S
    Hell J Nucl Med; 2021; 24(2):140-148. PubMed ID: 34352049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distant, solitary skeletal muscle metastasis in recurrent papillary thyroid carcinoma.
    Bae SY; Lee SK; Koo MY; Hur SM; Choi MY; Cho DH; Choe JH; Kim JH; Kim JS
    Thyroid; 2011 Sep; 21(9):1027-31. PubMed ID: 21834676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between BRAFV600E, NF-κB and TgAb expression in papillary thyroid carcinoma.
    Li W; Ming H; Sun D; Li W; Wang D; Zhang G; Tan J
    Pathol Res Pract; 2017 Mar; 213(3):183-188. PubMed ID: 28214213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SIMULTANEOUS METASTASES OF PAPILLARY THYROID CARCINOMA AND NEUROENDOCRINE TUMOR OF THE CECUM TO CERVICAL LYMPH NODES: A CASE REPORT.
    Romić M; Blažeković I; Mateša N; Franceschi M; Šiško-Markoš I; Kusić Z; Fröbe A; Jukić T
    Acta Clin Croat; 2023 Apr; 62(1):230-233. PubMed ID: 38304356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic metastasis of papillary thyroid carcinoma preoperatively diagnosed by endoscopic ultrasound-guided fine-needle aspiration biopsy: a case report with review of literatures.
    Murakami Y; Shimura T; Okada R; Kofunato Y; Ishigame T; Yashima R; Nakano K; Suzuki S; Takenoshita S
    Clin J Gastroenterol; 2018 Dec; 11(6):521-529. PubMed ID: 29948817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
    Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
    Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
    [No Abstract]   [Full Text] [Related]  

  • 11. Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma.
    Kim SK; So Y; Chung HW; Yoo YB; Park KS; Hwang TS; Kim B; Lee WW
    Cancer Med; 2016 Oct; 5(10):2756-2762. PubMed ID: 27539659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.
    Kim MH; Ko SH; Bae JS; Lee SH; Jung CK; Lim DJ; Baek KH; Kim SH; Lee JM; Kang MI; Cha BY
    Thyroid; 2013 Nov; 23(11):1452-60. PubMed ID: 23688271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
    Hung MC; Wu HS; Kao CH; Chen WK; Changlai SP
    Endocr Res; 2003 May; 29(2):169-75. PubMed ID: 12856803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
    Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
    Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum antithyroglobulin antibodies interfere with thyroglobulin detection in fine-needle aspirates of metastatic neck nodes in papillary thyroid carcinoma.
    Jeon MJ; Park JW; Han JM; Yim JH; Song DE; Gong G; Kim TY; Baek JH; Lee JH; Shong YK; Kim WB
    J Clin Endocrinol Metab; 2013 Jan; 98(1):153-60. PubMed ID: 23144473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Euthyroid status after total thyroidectomy due to functioning lung metastases from a clear cell variant of papillary thyroid carcinoma.
    Lee JI; Chung YJ; Park SJ; Ryu HS; Cho BY
    Thyroid; 2012 Oct; 22(10):1084-7. PubMed ID: 22873179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical Lymph Node Fine-Needle Aspiration and Needle-Wash Thyroglobulin Reflex Test for Papillary Thyroid Carcinoma.
    Zhang X; Howell JM; Huang Y
    Endocr Pathol; 2018 Dec; 29(4):346-350. PubMed ID: 30203321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
    Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
    Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.